115 related articles for article (PubMed ID: 33365366)
1. Data on estimations of relative dose rates along central axis of symmetric and asymmetric
Paiva E
Data Brief; 2021 Feb; 34():106620. PubMed ID: 33365366
[TBL] [Abstract][Full Text] [Related]
2. Estimates of relative beta radiation doses on central and lateral axes of ruthenium/rhodium COB-type plaque used in eye brachytherapy.
De Paiva E
Appl Radiat Isot; 2020 Feb; 156():108991. PubMed ID: 32056686
[TBL] [Abstract][Full Text] [Related]
3. Absorbed dose distributions from ophthalmic
Hermida-López M; Brualla L
Med Phys; 2018 Apr; 45(4):1699-1707. PubMed ID: 29399810
[TBL] [Abstract][Full Text] [Related]
4. Surface dose rate variations in planar and curved geometries of
Bakshi AK; Shrivastava V; Chattaraj A; Samuel K; Palani Selvam T; Sapra BK; Sinharoy P; Banerjee D; Sugilala G; Manohar S; Kaushik CP
Phys Med; 2021 Sep; 89():200-209. PubMed ID: 34399207
[TBL] [Abstract][Full Text] [Related]
5. A convex windowless extrapolation chamber to measure surface dose rate from
Hansen JB; Culberson WS; DeWerd LA
Med Phys; 2019 May; 46(5):2430-2443. PubMed ID: 30873611
[TBL] [Abstract][Full Text] [Related]
6. A patch source model for treatment planning of ruthenium ophthalmic applicators.
Astrahan MA
Med Phys; 2003 Jun; 30(6):1219-28. PubMed ID: 12852546
[TBL] [Abstract][Full Text] [Related]
7. Comparison between beta radiation dose distribution due to LDR and HDR ocular brachytherapy applicators using GATE Monte Carlo platform.
Mostafa L; Rachid K; Ahmed SM
Phys Med; 2016 Aug; 32(8):1007-18. PubMed ID: 27499370
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo calculation of the dose distributions of two 106Ru eye applicators.
Sánchez-Reyes A; Tello JI; Guix B; Salvat F
Radiother Oncol; 1998 Nov; 49(2):191-6. PubMed ID: 10052886
[TBL] [Abstract][Full Text] [Related]
9. Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code.
Hermida-López M
Med Phys; 2013 Oct; 40(10):101705. PubMed ID: 24089895
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric Investigation of Six Ru-106 Eye Plaques by EBT3 Radiochromic Films and Monte Carlo Simulation.
Arjmand M; Ghassemi F; Rafiepour P; Zeinali R; Riazi-Esfahani H; Beiki-Ardakani A
J Biomed Phys Eng; 2023 Aug; 13(4):309-316. PubMed ID: 37609514
[TBL] [Abstract][Full Text] [Related]
11. On the actual state of industrial quality assurance procedures with regard to (106)Ru ophthalmic plaques.
Kaulich TW; Zurheide J; Haug T; Budach W; Nüsslin F; Bamberg M
Strahlenther Onkol; 2004 Jun; 180(6):358-64. PubMed ID: 15175870
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium-106 brachytherapy.
Pe'er J
Dev Ophthalmol; 2012; 49():27-40. PubMed ID: 22042011
[TBL] [Abstract][Full Text] [Related]
13. Technical Note: Monte Carlo study of
Hermida-López M; Brualla L
Med Phys; 2017 Jun; 44(6):2581-2585. PubMed ID: 28370303
[TBL] [Abstract][Full Text] [Related]
14. Calculation of beta-ray dose distributions from ophthalmic applicators and comparison with measurements in a model eye.
Cross WG; Hokkanen J; Järvinen H; Mourtada F; Sipilä P; Soares CG; Vynckier S
Med Phys; 2001 Jul; 28(7):1385-96. PubMed ID: 11488569
[TBL] [Abstract][Full Text] [Related]
15. Cerenkov Luminescence Imaging for Accurate Placement of Radioactive Plaques in Episcleral Brachytherapy of Intraocular Tumors.
Axelsson J; Krohn J
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7362-8. PubMed ID: 26562170
[TBL] [Abstract][Full Text] [Related]
16. [Brachytherapy using Ru-106 applicators in ophthalmology].
Binder W; Menapace R; Seitz W
Strahlenther Onkol; 1990 Oct; 166(10):639-42. PubMed ID: 2237745
[TBL] [Abstract][Full Text] [Related]
17. Modified Geometry of
Miras H; Terrón JA; Bertolet A; Leal A
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629144
[TBL] [Abstract][Full Text] [Related]
18. A simple calibration method for 106Ru-106Rh eye applicators.
Kovacević N; Vrtar M; Vekić B
Radiother Oncol; 2005 Mar; 74(3):293-9. PubMed ID: 15763310
[TBL] [Abstract][Full Text] [Related]
19. Multidimensional dosimetry of ¹⁰⁶Ru eye plaques using EBT3 films and its impact on treatment planning.
Heilemann G; Nesvacil N; Blaickner M; Kostiukhina N; Georg D
Med Phys; 2015 Oct; 42(10):5798-808. PubMed ID: 26429254
[TBL] [Abstract][Full Text] [Related]
20. [Therapy relevant weak sites in industrial quality assurance of 106Ru eye plaques].
Kaulich TW; Zurheide J; Flühs D; Haug T; Nüsslin F; Bamberg M
Strahlenther Onkol; 2001 Nov; 177(11):616-23; discussion 624-7. PubMed ID: 11757185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
